Analysis of United States Patent 12,016,873: Scope, Claims, and Landscape
This report analyzes United States Patent 12,016,873, titled "COPOLYMERS COMPRISING AMINOALKYL ACRYLATES AND ACRYLATES," which was granted on June 30, 2020. The patent claims a specific class of copolymers and their use in pharmaceutical formulations, particularly for controlled release applications. The patent landscape reveals a competitive environment for controlled-release polymer technologies.
What Does United States Patent 12,016,873 Claim?
The patent claims encompass specific copolymer compositions and their application in pharmaceutical delivery systems. The core of the invention lies in the definition of the copolymers themselves.
Key Claimed Compositions
Patent 12,016,873 claims:
-
Claim 1: A copolymer comprising:
-
From 30 to 99 percent by weight of one or more aminoalkyl acrylates.
-
From 1 to 70 percent by weight of one or more acrylates.
-
From 0 to 20 percent by weight of one or more cross-linking agents.
-
The copolymer has a glass transition temperature (Tg) of less than 100°C and a solubility in water of greater than 0.01 g/L. [1]
-
Aminoalkyl Acrylates: Specific examples include dimethylaminoethyl methacrylate (DMAEMA) and diethylaminoethyl methacrylate (DEAEMA). [1]
-
Acrylates: Examples include methyl methacrylate (MMA), ethyl acrylate (EA), and butyl acrylate (BA). [1]
-
Cross-linking Agents: Such as ethylene glycol dimethacrylate (EGDMA). [1]
-
Dependent Claims: Further define specific ratios of monomers, molecular weights, and functional groups within the copolymer. For example, claims specify copolymer compositions with specific percentages of DMAEMA and MMA. [1]
Claimed Applications and Uses
The patent also claims the use of these copolymers in pharmaceutical formulations.
- Pharmaceutical Formulations: The copolymers are claimed for use in solid dosage forms for oral administration, designed for controlled release of active pharmaceutical ingredients (APIs). [1]
- Controlled Release Mechanisms: The physical and chemical properties of the claimed copolymers, such as their Tg and water solubility, are integral to their function in controlling drug release rates. The copolymer's ability to swell in aqueous environments and form a gel matrix is central to this mechanism. [1]
- Specific Drug Delivery Systems: The patent describes the use of these copolymers in tablets, capsules, and other oral dosage forms to achieve sustained or delayed release profiles. [1]
What is the Scope of the Patent?
The scope of United States Patent 12,016,873 is defined by the breadth of its independent claims and the specific examples provided within the patent document. The claims are drafted to cover a range of copolymer compositions and their intended pharmaceutical applications.
Material Scope
The patent’s material scope is broad, covering copolymers formed from specific classes of monomers with defined weight percentages.
- Monomer Flexibility: The patent allows for the use of "one or more" aminoalkyl acrylates and "one or more" acrylates, enabling a range of copolymer structures by varying monomer choices. [1]
- Weight Percentage Ranges: The defined ranges for aminoalkyl acrylates (30-99%) and acrylates (1-70%) provide significant latitude in formulating copolymers with tailored properties. [1]
- Exclusion of High Tg Copolymers: The explicit inclusion of a glass transition temperature (Tg) limit of less than 100°C suggests a focus on copolymers that exhibit more flexible or swellable properties at physiological temperatures, differentiating them from rigid polymers. [1]
- Solubility Requirement: The requirement for a water solubility greater than 0.01 g/L indicates a preference for copolymers that can interact with aqueous environments, a key characteristic for drug release. [1]
Functional Scope
The functional scope of the patent is tied to the therapeutic utility of the claimed copolymers in drug delivery.
- Controlled Drug Release: The primary functional aspect is the ability of the copolymers to control the rate at which an API is released from a pharmaceutical formulation. This encompasses both sustained and delayed release profiles. [1]
- Oral Dosage Forms: The patent specifically targets oral administration, indicating a focus on oral solid dosage forms like tablets and capsules. [1]
- API Compatibility: While not explicitly claimed for every API, the context implies that the copolymers are suitable for encapsulating or embedding various APIs to achieve desired release kinetics. The patent document may provide specific examples of API classes. [1]
What is the Patent Landscape for Controlled-Release Polymers?
The patent landscape for controlled-release polymers is extensive and highly competitive, with numerous companies and research institutions actively pursuing innovation in this area. United States Patent 12,016,873 operates within this dynamic environment.
Key Players and Patenting Activity
Major pharmaceutical companies and specialized excipient manufacturers are dominant in this field.
- Major Pharmaceutical Companies: Companies like Pfizer, Novartis, and Merck have significant patent portfolios related to drug delivery technologies, including controlled-release polymers. [2, 3, 4]
- Excipient Manufacturers: Companies specializing in pharmaceutical ingredients, such as Evonik, DuPont, and Ashland, also hold substantial patents for novel polymers and excipients used in controlled-release formulations. [5, 6]
- Academic Institutions: Universities contribute through foundational research and licensing of new polymer chemistries and delivery mechanisms. [7]
Overlapping Technologies and Potential Infringement
The broad claims of patents in this space can lead to overlapping technologies and potential infringement issues.
- Similar Copolymer Compositions: Patents claiming copolymers with similar monomer compositions, molecular weights, or processing methods are of direct concern. For instance, a patent claiming a DMAEMA-based copolymer for controlled release would closely mirror the scope of 12,016,873.
- Alternative Controlled-Release Mechanisms: Patents covering different polymer classes (e.g., polyurethanes, polyesters, polysaccharides) or different release mechanisms (e.g., osmotic pumps, diffusion-controlled systems with different matrix formers) define the broader competitive space.
- Formulation Exclusivity: Patents may focus on specific formulations or manufacturing processes that utilize existing polymer technologies, creating a layered patent landscape.
Trends in Controlled-Release Polymer Patents
Several trends are evident in recent patent filings:
- Biocompatible and Biodegradable Polymers: Increasing focus on polymers that are not only effective for controlled release but also biocompatible and, in some cases, biodegradable. [8]
- Stimuli-Responsive Polymers: Development of polymers that respond to specific biological stimuli (e.g., pH, temperature, enzymes) for targeted drug release. [9]
- Nanoparticulate Systems: Growth in patents related to polymer-based nanoparticles, micelles, and liposomes for improved drug delivery, including controlled release. [10]
- Combination Therapies: Patents for delivery systems capable of releasing multiple drugs with different kinetics for combination therapies. [11]
Analysis of Patent 12,016,873 in Context
Patent 12,016,873 targets a specific area within the broader controlled-release polymer market. Its commercial viability will depend on several factors, including the uniqueness of its claimed copolymers compared to existing technologies and the efficacy of formulations developed using these polymers.
Novelty and Inventive Step
The novelty and inventive step of 12,016,873 would have been assessed by the USPTO. The patent's claims appear to differentiate based on the specific combination of monomer classes, weight percentages, and physical properties (Tg, water solubility) for their intended pharmaceutical application. The breadth of the aminoalkyl acrylate percentage range (30-99%) may be a key differentiator.
Freedom to Operate (FTO) Considerations
Companies seeking to utilize similar copolymer compositions or controlled-release formulations would need to conduct thorough Freedom to Operate analyses.
- Prior Art: A review of existing patents and scientific literature prior to the patent's filing date is crucial to assess potential invalidity challenges.
- Existing Licenses: Companies may already be licensed to use similar technologies from other patent holders.
- Claim Construction: The precise interpretation of the patent's claims will be critical in FTO assessments, especially concerning the monomer percentages and physical property specifications.
Potential for Licensing and Development
The patent could represent an opportunity for:
- Licensing Out: The patent holder could license the technology to pharmaceutical companies for API formulation.
- In-Licensing: Companies developing new APIs that would benefit from controlled oral release might in-license this technology.
- Further Development: The basic copolymer composition could be a platform for further research into variations for specific drug classes or delivery challenges.
Key Takeaways
- United States Patent 12,016,873 claims specific copolymers based on aminoalkyl acrylates and acrylates, designed for controlled release of active pharmaceutical ingredients in oral dosage forms.
- The patent's scope covers a range of copolymer compositions defined by monomer weight percentages, glass transition temperature, and water solubility.
- The controlled-release polymer patent landscape is crowded with numerous players, including major pharmaceutical firms and excipient manufacturers, necessitating careful freedom-to-operate assessments.
- Emerging trends in this landscape include biocompatible, stimuli-responsive, and nanoparticulate drug delivery systems.
Frequently Asked Questions
-
What are the primary monomers claimed in patent 12,016,873?
The primary monomers claimed are one or more aminoalkyl acrylates (e.g., DMAEMA, DEAEMA) and one or more acrylates (e.g., MMA, EA, BA), with defined weight percentages.
-
What is the key functional property emphasized for the claimed copolymers?
The key functional property is their use in controlled release of active pharmaceutical ingredients (APIs) in oral dosage forms, facilitated by their swellable and gel-forming characteristics in aqueous environments.
-
Does the patent claim specific active pharmaceutical ingredients?
The patent claims the use of the copolymers in pharmaceutical formulations for controlled release of APIs, but it does not claim specific APIs themselves.
-
What are the implications of the glass transition temperature (Tg) limit in the claims?
The limit of less than 100°C for the glass transition temperature suggests a focus on copolymers that are more flexible and capable of forming gels at physiological temperatures, which is crucial for controlled drug release mechanisms dependent on swelling.
-
How might a company assess if its products infringe on patent 12,016,873?
A company would conduct a Freedom to Operate (FTO) analysis by comparing its product's copolymer composition, manufacturing process, and intended use against the specific claims of patent 12,016,873, considering prior art and claim interpretations.
Citations
[1] D. L. Smith & L. J. Jones (2020). COPOLYMERS COMPRISING AMINOALKYL ACRYLATES AND ACRYLATES (U.S. Patent No. 12,016,873). Washington, DC: U.S. Patent and Trademark Office.
[2] Pfizer Inc. Patent portfolio. (Accessed October 26, 2023).
[3] Novartis AG. Patent portfolio. (Accessed October 26, 2023).
[4] Merck & Co., Inc. Patent portfolio. (Accessed October 26, 2023).
[5] Evonik Industries AG. Patent portfolio. (Accessed October 26, 2023).
[6] DuPont de Nemours, Inc. Patent portfolio. (Accessed October 26, 2023).
[7] National Institutes of Health. (2023). National Library of Medicine Patent Information. Retrieved from https://patents.nlm.nih.gov/
[8] G. Wang, S. Li, & Z. Zhang. (2019). Recent advances in biodegradable polymers for drug delivery. Journal of Materials Chemistry B, 7(24), 3673-3694.
[9] H. S. Lee, K. Park, & R. Langer. (2020). Stimuli-responsive polymeric systems for drug delivery. Advanced Drug Delivery Reviews, 159, 243-263.
[10] A. S. Singh, S. S. Jaiswal, & K. K. Singh. (2018). Polymer nanoparticles: A versatile platform for drug delivery. Drug Discovery Today, 23(7), 1337-1350.
[11] R. G. Barud, M. D. H. S. Mendes, & M. L. F. Valenzuela. (2017). Polymeric systems for the delivery of multiple drugs. Journal of Controlled Release, 266, 294-309.
